-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

An Anti-CD38 Directed Antibody for the Treatment for Appropriate Patients with Relapsed Refractory Multiple Myeloma

Program: Product Theaters
Session: An Anti-CD38 Directed Antibody for the Treatment for Appropriate Patients with Relapsed Refractory Multiple Myeloma
Sunday, December 6, 2020, 11:00 AM-12:00 PM

Megan Sell, NP

Sanofi Genzyme, Cambridge, MA

Disclosures: No relevant conflicts of interest to declare.

See more of: An Anti-CD38 Directed Antibody for the Treatment for Appropriate Patients with Relapsed Refractory Multiple Myeloma
See more of: Product Theaters